MBCProject_2346_T1_RNA
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.260
- PROTEIN_SECRETION+0.180
- SPERMATOGENESIS+0.180
- TGF_BETA_SIGNALING+0.180
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.170
- DNA_REPAIR+0.150
- E2F_TARGETS+0.140
- G2M_CHECKPOINT+0.120
- UV_RESPONSE_DN+0.110
- ANDROGEN_RESPONSE+0.050
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- INTERFERON_GAMMA_RESPONSE-0.520
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.460
- ALLOGRAFT_REJECTION-0.430
- IL6_JAK_STAT3_SIGNALING-0.380
- COMPLEMENT-0.350
- WNT_BETA_CATENIN_SIGNALING-0.340
- UV_RESPONSE_UP-0.310
- INFLAMMATORY_RESPONSE-0.300
- IL2_STAT5_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R157 | — | — | 0.832 |
| 2 | TCGA-AR-A24K-01A-11R-A169-07 | — | B | 0.823 |
| 3 | s0122172 | — | — | 0.815 |
| 4 | MBCProject_6127_T1_RNA | — | B | 0.812 |
| 5 | TCGA-BH-A204-01A-11R-A157-07 | — | B | 0.811 |
| 6 | 62b39052-bdb9-4ba6-9eb0-f117480c98a8 | — | — | 0.810 |
| 7 | ERR2208889 | — | — | 0.805 |
| 8 | BS_4CP4T22V | medulloblastoma | — | 0.803 |
| 9 | SRR10900006 | — | — | 0.801 |
| 10 | SRR5088922 | — | — | 0.799 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.140 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.050 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.040 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.030 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.030 | Inavolisib | — uncovered |